Kiniksa Pharmaceuticals, Ltd. (KNSA)

Kiniksa Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	107.95	122.72	122.47	114.25	46.93
Short-Term Investments	98.42	67.89	59.73	209.44	186.45
Cash & Cash Equivalents	206.37	190.61	182.2	323.69	233.38
Cash Growth	8.27%	4.61%	-43.71%	38.70%	-24.11%
Receivables	21.27	12.66	3.99	0	0
Inventory	31.12	21.6	3.68	0	0
Other Current Assets	17.54	18.19	6.59	9.56	8.25
Total Current Assets	276.3	243.06	196.45	333.25	241.63
Property, Plant & Equipment	12.67	7.04	8.38	10.62	8.33
Long-Term Investments	0	0	0	0	0.21
Goodwill and Intangibles	17.25	18.25	19.25	0	0
Other Long-Term Assets	220.11	191.32	8.72	5.6	4.37
Total Long-Term Assets	250.03	216.61	36.35	16.22	12.91
Total Assets	526.32	459.67	232.8	349.46	254.53
Accounts Payable	8.25	7.9	1.87	0.5	5.69
Deferred Revenue	12.26	12	0	0	0
Current Debt	2.25	3.3	3.38	2.11	1.7
Other Current Liabilities	40.91	23.87	39.58	29.24	20.44
Total Current Liabilities	63.67	47.07	44.82	31.85	27.83
Long-Term Debt	10.01	2.62	2.67	4.88	0.96
Other Long-Term Liabilities	13.81	13.84	0.27	0.81	0.33
Total Long-Term Liabilities	23.82	16.46	2.94	5.68	1.28
Total Liabilities	87.48	63.52	47.76	37.53	29.11
Total Debt	12.26	5.92	6.05	6.99	2.65
Debt Growth	107.10%	-2.17%	-13.39%	163.39%	-
Retained Earnings	-477.95	-492.03	-675.4	-517.47	-356.09
Comprehensive Income	0.01	0.04	-0.07	-0.03	0.03
Shareholders' Equity	438.84	396.15	185.04	311.94	225.42
Net Cash / Debt	194.11	184.69	176.15	316.71	230.73
Net Cash / Debt Growth	5.10%	4.85%	-44.38%	37.26%	-24.97%
Net Cash Per Share	2.70	2.62	2.57	5.12	4.27
Working Capital	212.63	195.99	151.62	301.4	213.8
Book Value Per Share	6.26	5.71	2.70	5.04	4.17

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).